The Interferon Antagonist NS2 Protein of Respiratory Syncytial Virus Is an Important Virulence Determinant for Humans
The Journal of Infectious Diseases2006Vol. 193(4), pp. 573–581
Citations Over TimeTop 10% of 2006 papers
Peter F. Wright, Ruth A. Karron, Shabir A. Madhi, John J. Treanor, James C. King, Alice O’Shea, Mine R. Ikizler, Yuwei Zhu, Peter L. Collins, Clare Cutland, Valerie B. Randolph, Anne M. Deatly, Jill Hackell, William C. Gruber, Brian R. Murphy
Abstract
Deletion of the NS2 gene attenuates RSV in subjects of all ages studied. This validates the strategy of developing live respiratory tract virus vaccines in which the virus's ability to inhibit the human innate immune system is blocked. rA2cp248/404 Delta NS2 should be studied in children at a higher input titer, because it was more infectious and immunogenic than was rA2cp530/1009 Delta NS2.
Related Papers
- → Generation by reverse genetics of an effective attenuated Newcastle disease virus vaccine based on a prevalent highly virulent Chinese strain(2015)45 cited
- → Paramyxoviruses: Respiratory Syncytial Virus and Human Metapneumovirus(2014)13 cited
- → Pneumoviruses: Respiratory Syncytial Virus and Human Metapneumovirus(2022)3 cited
- → The late detection of respiratory syncytial virus in cells of respiratory tract by immunofluorescence(1970)59 cited
- → Improved detection of respiratory syncytial virus in nasal aspirates by seminested RT‐PCR(1997)